<DOC>
	<DOCNO>NCT00006258</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow radiation therapy treat patient surgically resect , newly diagnose medulloblastoma supratentorial primitive neuroectodermal tumor , incompletely resect ependymoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Radiation Therapy Treating Patients With Medulloblastoma , Supratentorial Primitive Neuroectodermal Tumor , Ependymoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity adjuvant dose-intensive induction chemotherapy cisplatin , vincristine , cyclophosphamide , etoposide without methotrexate follow standard radiotherapy patient surgically resect , newly diagnose high stage medulloblastoma supratentorial primitive neuroectodermal tumor , incompletely resect ependymoma . - Determine response rate , time progression , overall survival , pattern failure patient treat regimen . OUTLINE : Patients receive dose-intensive induction chemotherapy consist cisplatin IV 6 hour day 0 ; vincristine IV day 0 , 7 , 14 ; etoposide cyclophosphamide IV 1 hour day 1 2 . Patients M1+ disease ( i.e. , evidence dissemination beyond primary tumor site ) also receive methotrexate IV 4 hour day 3 . Patients receive filgrastim ( G-CSF ) subcutaneously daily begin day 7 continue blood count recover . Chemotherapy continue every 21-28 day total 3 course absence disease progression unacceptable toxicity . Patients undergo radiotherapy 5 day week 6.5 week begin 3-6 week completion chemotherapy . Patients follow 6 week , every 3 month 2 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 6-20 patient accrue study .</detailed_description>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histological confirmation one following : High stage medulloblastoma neuraxis dissemination ( Chang stage M1 great ) Primitive neuroectodermal tumor Ependymoma Incompletely resect postoperative MRI neurosurgical report Definitive prior surgery within 42 day study PATIENT CHARACTERISTICS : Age : 10 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 mg/dL SGPT le 2.5 time upper limit normal Renal : Creatinine clearance great 60 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow No concurrent corticosteroid antiemetic Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
</DOC>